製藥業合作協議：2021-2026 年

本報告將幫助您了解製藥公司如何建立合作關係，以利用創新、分擔研發風險並結合其互補能力。

本報告提供了有關 1404 項涉及製藥公司的合作交易的全面資訊。

本報告檢驗了製藥公司如何利用合作協議來獲取技術、能力和發展機會，與外部合作夥伴合作，並透過研發和商業化推動資產發展。

這份報告不僅僅是列出交易；它還能幫助您了解誰與誰合作，交易活動集中在哪些地方，合約是如何建構的，以及可以從揭露的財務條款和公開的合約文件中了解到什麼。

本報告為製藥業的業務發展、許可、研究和評估、公司策略、研發策略、合作夥伴關係管理以及負責人評估和談判合作夥伴關係的法律團隊提供可操作的資訊和基準資源。

了解製藥業合作關係的全貌

本報告分析了2021年至2026年合夥交易的以下幾個面向：

• 合夥交易的年度趨勢
• 合作關係建立時的發展階段
• 產業部門
• 治療區域
• 技術類型
• 合作交易最活躍的公司
• 根據已披露的交易金額，主要交易
• 簽訂合作協議的策略性原因
• 製藥公司合作策略的變化
• 這使我們能夠了解合作集中在哪些領域，以及製藥公司如何利用外部合作夥伴關係來應對各種技術、治療領域和開發階段。
• 了解合夥協議的結構
• 該合作協議涵蓋了與研究、開發和商業化相關的廣泛合作。

本報告提供以下資訊供您參考：

• 研發職責
• 授予的權利或選擇權
• 發展資金和成本分配
• 智慧財產權的所有權和權利
• 管治與決策
• 獨家條款
• 關於開發和監管的職責
• 製造/供應
• 商業化方面的權利和責任
• 區域和市場特定權利
• 如已揭露財務狀況
• 合約期限和終止條款
• 這些資訊對於評估潛在合作模式的團隊和準備合作洽談的團隊都將有所幫助。
• 關鍵交易和已揭露財務狀況的基準分析
• 本報告根據已揭露的交易額，確定了主要的製藥業合作關係，並提供了與每項協議相關的可用財務資訊。

可查核的主要財務項目如下：

• 預付款
• 開發和監管里程碑
• 商業化里程碑
• 忠誠條款
• 與股票相關的因素
• 其他財務承諾
• 這使我們能夠將潛在的交易與實際類似的合作案例進行比較，並在進行交易談判之前獲得更準確的資訊。
• 確定關鍵合作夥伴公司
• 本報告重點關注合作最活躍的前 25 家公司，並分析經常進行聯合合作的製藥和生物技術公司。

回顧每家公司過去的交易歷史有助於了解它們如何看待外部創新和支援。

• 尋找潛在合作夥伴公司
• 搜尋和評分
• 競爭分析
• 業務發展策略
• 夥伴關係活動評估
• 從實際合約文件中學習
• 本報告在公開可取得的情況下，提供了相關合作協議的原文。
• 這些協議包含僅憑公司新聞稿無法獲得的詳細信息，使您可以了解每個合作夥伴公司如何就開發義務、智慧財產權、排他性、管治、財務安排、商業化權利和合約終止做出安排。
• 對於準備和談判合作協議的團隊來說，這些實際合約有助於了解類似交易在實踐中是如何記錄的。
• 綜合合作夥伴名錄
• 本報告包含 1,404 項醫藥合作交易的綜合目錄，使您能夠找到與貴公司資產、技術和合作目標相關的交易。

目錄

摘要整理

第1章：引言

第2章 合夥交易趨勢

• 合夥協議的定義
• 合作協議的趨勢
  • 合夥交易數量（按年統計）
  • 按發展階段分類的合作交易數量
  • 按行業分類的合作交易數量
  • 合作交易數量：按治療區域分類
  • 按技術類型分類的合作交易數量
  • 合作交易數量：依最活躍的公司統計
• 簽訂合夥協議的理由
• 夥伴關係的未來

第3章 合夥協議的結構：概述

• 合夥協議的結構

第4章 主要合夥協議

• 按以金額為準的前幾名合作協議

第5章：合作交易最活躍的25家公司

• 最活躍的25家合作夥伴

第6章 合夥交易目錄（含合約）

• 可以審查合約的合夥交易。
• 交易目錄
• 交易目錄：依公司名稱（A-Z）
• 交易目錄：依治療領域
• 交易目錄：依技術類型
• 關於生物製藥研究
• Current Partnering
• Current Agreements
• 理想合作夥伴近期報告標題

Understand how pharmaceutical companies structure collaboration partnerships to access innovation, share development risk and combine complementary capabilities.

Collaboration Deals in Pharmaceuticals provides comprehensive intelligence on 1,404 collaboration deals involving pharmaceutical companies.

The report examines how pharmaceutical companies use collaboration agreements to access technologies, capabilities and development opportunities, work with external partners and advance assets through research, development and commercialization.

Rather than simply identifying transactions, the report enables users to understand who is collaborating, where deal activity is concentrated, how agreements are structured, and what can be learned from disclosed financial terms and publicly available contract documents.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, alliance management and legal teams involved in evaluating or negotiating pharmaceutical collaborations.

Understand the pharmaceutical collaboration landscape

The report analyzes collaboration dealmaking from 2021 to 2026, including:

• Trends in collaboration dealmaking by year
• Stage of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active collaboration dealmakers
• Leading deals by disclosed value
• Strategic reasons for entering collaboration agreements
• How pharmaceutical collaboration strategies are evolving
• This provides a clear view of where collaboration activity is concentrated and how pharmaceutical companies are using external partnerships across different technologies, therapeutic areas and stages of development.
• Understand how collaboration agreements are structured
• Collaboration agreements can encompass a wide range of research, development and commercialization relationships.

The report provides intelligence to help users examine areas including:

• Research and development responsibilities
• Rights granted or optioned
• Development funding and cost allocation
• Intellectual property ownership and rights
• Governance and decision-making
• Exclusivity provisions
• Development and regulatory responsibilities
• Manufacturing and supply
• Commercialization rights and responsibilities
• Geographic and market rights
• Financial terms where disclosed
• Term and termination provisions
• This provides useful reference points for teams assessing potential collaboration models or preparing for partnering discussions.
• Benchmark leading deals and disclosed financial terms
• The report identifies leading pharmaceutical collaboration transactions by disclosed deal value and provides access to available financial information associated with individual agreements.

Users can investigate disclosed elements including:

• Upfront payments
• Development and regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity components
• Other financial commitments where available
• This helps users place potential transactions into the context of comparable real-world collaborations and develop more informed positions ahead of deal discussions.
• Identify leading collaboration dealmakers
• The report profiles the Top 25 most active collaboration dealmakers, providing insight into the pharmaceutical and biotechnology companies most frequently entering collaborative partnerships.

Individual deal histories can help users understand how particular companies approach external innovation and support:

• Partner identification
• Search and evaluation
• Competitor analysis
• Business development strategy
• Assessment of partnering behaviour
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying collaboration contract documents.
• These agreements can reveal substantially more detail than company announcements alone, enabling users to examine how selected partners have addressed areas such as development obligations, intellectual property, exclusivity, governance, financial arrangements, commercialization rights and termination.
• For teams preparing for or negotiating collaboration agreements, these real-world contracts provide valuable insight into how comparable transactions have been documented in practice.
• Comprehensive collaboration deal directory
• The report includes a comprehensive directory of 1,404 pharmaceutical collaboration deals, enabling users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable deals, potential partners and relevant structures when evaluating or preparing pharmaceutical collaborations.
• Search and Evaluation teams
• Understand which companies are partnering in specific technology, therapy and development areas and investigate their previous transaction activity.
• Corporate and R&D Strategy teams
• Track how pharmaceutical companies are using external collaborations to access innovation and complement internal development capabilities.
• Alliance Management teams
• Examine how development responsibilities, governance and ongoing partner obligations have been structured across comparable agreements.
• Legal and Transaction teams
• Review deal structures and publicly available contract language to support transaction preparation and negotiation.
• Competitive and Market Intelligence teams
• Analyze collaboration activity by company, therapy area, technology and development stage to identify important partnering trends.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying collaboration intelligence to the customer's own business, assets, technologies or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaboration dealmaking

• 2.1. Introduction
• 2.2. Definition of collaboration deal
• 2.3. Trends in collaboration deals
  • 2.3.1. Collaboration dealmaking by year
  • 2.3.2. Collaboration dealmaking by phase of development
  • 2.3.3. Collaboration dealmaking by industry sector
  • 2.3.4. Collaboration dealmaking by therapy area
  • 2.3.5. Collaboration dealmaking by technology type
  • 2.3.6. Collaboration dealmaking by most active company
• 2.4. Reasons for entering into collaboration partnering deals
• 2.5. The future of collaboration deals

Chapter 3 - Overview of collaboration deal structure

• 3.1. Introduction
• 3.2. Collaboration agreement structure

Chapter 4 - Leading collaboration deals

• 4.1. Introduction
• 4.2. Top collaboration deals by value

Chapter 5 - Top 25 most active collaboration dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active collaboration dealmakers

Chapter 6 - Collaboration deals including contracts directory

• 6.1. Introduction
• 6.2. Collaboration deals with contracts
• Deal directory
• Deal directory - collaboration dealmaking by companies A-Z
• Deal directory - collaboration dealmaking by therapy area
• Deal directory - collaboration dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of collaboration deal
• Figure 2: Trends in collaboration deal announcements
• Figure 3: Collaboration deals signed at each phase of development
• Figure 4: Collaboration deals by industry sector
• Figure 5: Collaboration deals by therapy area
• Figure 6: Collaboration deals by technology type
• Figure 7: Top 25 most active collaboration dealmakers
• Figure 8: Top collaboration deals by value
• Figure 9: Most active collaboration dealmakers